Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Edarbi - labeled renal guidance
Product / population
Azilsartan kamedoxomil (Edarbi), oral tablet
Renal method
Renal impairment categories as defined by the cited product label
Renal method: Renal impairment categories as defined by the cited product label Source date: DailyMed SPL version 17, posted Jan 31, 2024 Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Renal guidance: 5.3 Impaired Renal Function / 8.6 Renal Impairment
Mild through severe renal impairment and ESRD do not require adjustment of azilsartan medoxomil. Creatinine elevations were more frequent with moderate or severe impairment. Monitor renal function and review volume depletion and concomitant renin-angiotensin system blockers.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
